History and Scientific Team
Innovative company focused on the metabolic syndrome.
SJT Molecular Research was born from the know-how of the merger of Functional Products Innovation, S.L., and JT Scientific Development, S.L. all of which were doing research in pharmaceutical innovation since 2000.
Previous experience and a prestigious scientific team have transformed SJT Molecular Research into an outstanding company in terms of knowledge and research excellence.
In 1992, Mr. Juan Carlos Ágreda, recognized researcher and President and CEO of the company, started a series of research studies in Brazil, with a team of pharmacists, chemists, biologists, and agronomists.
The studies consisted in obtaining medicinal plants with anti-diabetic activity.
In 17 states of Brazil, samples of different plants were collected and analyzed. Their agronomic data was compiled, and their active chemical groups were analyzed.
Of the more than one hundred plant species identified with anti-diabetic properties, 34 were selected due to their pharmacological activity and lack of toxicity. Finally, due to their balanced synergy, two of the species were used to obtain an anti-diabetic formula that was validated animal models.
After analyzing the active principles of the two species and searching for structural similarities in collections of compounds, a family of molecules (1MY2AI-SJT-J) was obtained, This family, based on the β-carboline structure, was the origin of the project and the basis of our company.
Prestigious multidisciplinary team operating from several continents.
Under the coordination of Juan Carlos Ágreda, a qualified scientific team of external collaborators, companies, and universities collaborated with their know how and experience in the discovery research.
- Guided by Mr. Roberto M. Kassuya, Doctors María Élida Stefanello (Federal University of Paraná) and Cándida Aparecida Leite were in charge of the first tests.
- A research team from the University of Alcalá directed by Doctors José Luis Novella, Juan José Vaquero, and María Paz Matía performed the chemical synthesis of the molecules.
- A team from the University of the Balear Islands, performed the toxicological and pharmacologic tests, and different comparative tests against reference treatments.
- Doctors José A. Lamas and Antonio Reboreda, from the University of Vigo, worked in the identification of the mechanism of action.
- Doctor Manuel Illescas Taboada, coordinated the research work with the universities and developed patents.
In USA, France and Taipei
- Researchers from Eurofins-Panlabs CRO, Don Axworthy, Kun-Yuan Lin, Chien-Chang Shen, among others performed MoA studies, receptor binding, permeability, pharmacokinetics, bioavailability, solubility, insulin secretion ...
- Dr. Thierry Sulpice of Physiogenex CRO, conducted OGTT, ITT, hyperglycemia, hyperinsulinemia, HOMA-IR, overweight, and hepatic steatosis tests in normal murine models and DIO.
- Dr. Michael Feigh of Gubra CRO, conducted hepatic steatosis and NASH tests in DIO model.
In United Kingdom
- Doctors Fabio Spreafico and Nicholas Billinton of Gentronix CRO, lead toxicity studies.
- Dr. Janice Dunton of Sequani CRO, conducted genotoxicity studies.